Research programme: bacteria based therapeutics - Seres Therapeutics

Drug Profile

Research programme: bacteria based therapeutics - Seres Therapeutics

Alternative Names: SER 155; SER 301

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Seres Health
  • Developer Seres Therapeutics
  • Class Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Metabolic disorders
  • Research Graft-versus-host disease; Inflammation; Ulcerative colitis

Most Recent Events

  • 12 May 2016 Seres Therapeutics plans a clinical trial for Metabolic disorders in USA
  • 12 May 2016 Seres Therapeutics and University of Pennsylvania agree to co-develop bacteria based therapeutics in USA for Metabolic disorders
  • 04 May 2016 Seres Therapeutics enters into research collaboration with the Research Institute of St. Joseph's Hamilton and the Medical University of Graz to develop microbiome-based therapeutics for Inflammatory bowel disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top